UBS raised the firm’s price target on Veracyte (VCYT) to $46 from $43 and keeps a Buy rating on the shares post the earnings report.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter